SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 30.98+3.9%Dec 3 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (9570)4/11/1999 6:32:00 PM
From: Cacaito  Read Replies (2) of 17367
 
Robert K, I can hardly read the patent text. Anyway, not much new.
It is more of the same we have being posting for two years. Patience and to wait.

Re: Chlamydia, check post 9547.

George, Re: "net mortality" calculations are about complex mortality issues in Cancer. It seems to be for taking confounding information out of the way and the "net mortality" could be calculated. In case of menigococcemia it is not of much help due to the single nature of the etiology and the little confounding problems (healthy children). In the Trauma and cystic Fibrosis cases could be of help, or in septic geriatric patients with multiple established preconditions.

Re: Total Mortality, my number is 57 (low of 45, high of 75). Again, for this not much more to argue, but to wait and patience.

Bluegreen: look at Intrabiotics, they have Protegrin: a peptide antibiotic. It seems to have killing, but not inflammatory regulation abilities. (founded in Robert K's post 9589)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext